We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-3.83%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$928M
AUM Growth
-$21.2M
Cap. Flow
+$44.5M
Cap. Flow %
4.8%
Top 10 Hldgs %
34.27%
Holding
87
New
4
Increased
25
Reduced
17
Closed
2

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$9.79M
2
CRL icon
Charles River Laboratories
CRL
+$9.03M
3
ISRG icon
Intuitive Surgical
ISRG
+$7.34M
4
PRCT icon
Procept Biorobotics
PRCT
+$7.3M
5
MDT icon
Medtronic
MDT
+$6.95M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$9.98M
2
ZBH icon
Zimmer Biomet
ZBH
+$9.91M
3
ELV icon
Elevance Health
ELV
+$8.16M
4
UNH icon
UnitedHealth
UNH
+$6.89M
5
MOH icon
Molina Healthcare
MOH
+$6.54M

Sector Composition

Rank Sector Weight
1 Healthcare 99.51%
2 Industrials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMCR icon
51
Immunocore
IMCR
$1.75B
$4.63M 0.5%
89,278
– –
XNCR icon
52
Xencor
XNCR
$1.65B
$4.53M 0.49%
225,000
– –
RCM
53
DELISTED
R1 RCM Inc. Common Stock
RCM
$4.52M 0.49%
300,000
– –
IOVA icon
54
Iovance Biotherapeutics
IOVA
$2.94B
$4.32M 0.47%
950,000
+100,000
+12% +$653K
OSCR icon
55
Oscar Health
OSCR
$8.55B
$4.29M 0.46%
+770,000
New +$5.39M
DXCM icon
56
DexCom
DXCM
$33.4B
$4.2M 0.45%
+45,000
New +$5.07M
RVNC
57
DELISTED
Revance Therapeutics, Inc.
RVNC
$4.15M 0.45%
361,679
+238,679
+194% +$4.59M
RPRX icon
58
Royalty Pharma
RPRX
$26.1B
$4.07M 0.44%
150,000
– –
NUVL
59
DELISTED
Nuvalent
NUVL
$3.95M 0.43%
86,011
– –
EVH icon
60
Evolent Health
EVH
$461M
$3.95M 0.43%
145,000
– –
BBIO icon
61
BridgeBio Pharma
BBIO
$16.6B
$3.56M 0.38%
135,000
– –
WST icon
62
West Pharmaceutical
WST
$24.8B
$3.38M 0.36%
9,000
– –
HCAT icon
63
Health Catalyst
HCAT
$132M
$3.24M 0.35%
320,000
– –
MRNA icon
64
Moderna
MRNA
$23.7B
$3.1M 0.33%
30,000
-15,000
-33% -$1.67M
TECH icon
65
Bio-Techne
TECH
$11.2B
$2.91M 0.31%
42,680
-4,820
-10% -$381K
TXG icon
66
10x Genomics
TXG
$7.85B
$2.81M 0.3%
68,000
-68,000
-50% -$3.54M
AXSM icon
67
Axsome Therapeutics
AXSM
$11.4B
$2.8M 0.3%
40,100
– –
HRMY icon
68
Harmony Biosciences
HRMY
$2.29B
$2.67M 0.29%
81,474
-128,526
-61% -$4.46M
MGTX icon
69
MeiraGTx Holdings
MGTX
$1.21B
$2.65M 0.29%
538,986
– –
OLK
70
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$2.45M 0.26%
166,000
– –
CNC icon
71
Centene
CNC
$32.4B
$2.07M 0.22%
+30,000
New +$2M
EW icon
72
Edwards Lifesciences
EW
$53.6B
$2.01M 0.22%
29,000
– –
VKTX icon
73
Viking Therapeutics
VKTX
$3.98B
$1.99M 0.21%
180,000
– –
IGMS
74
DELISTED
IGM Biosciences
IGMS
$1.67M 0.18%
200,000
– –
ARVN icon
75
Arvinas
ARVN
$587M
$1.67M 0.18%
85,000
– –
1 2
3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2023 Portfolio in Review

As of Q3 2023, Rhenman & Partners Asset Management held 87 positions worth $928M, down 2.2% from $949M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rhenman & Partners Asset Management deployed $44.5M of net new capital in Q3 2023, opening 4 new positions and adding to 25 existing holdings. Its largest new stake was Charles River Laboratories: 44,000 shares worth $8.62M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Cigna, an estimated $9.98M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2023 buy was Charles River Laboratories: 44,000 shares worth $8.62M.
  • Rhenman & Partners Asset Management added most to Eli Lilly in Q3 2023, an estimated $9.79M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2023 reduction was Cigna, cutting an estimated $9.98M.
  • Rhenman & Partners Asset Management fully exited Molina Healthcare in Q3 2023, selling an estimated $6.54M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 34% of its $928M portfolio in Q3 2023.
  • Rhenman & Partners Asset Management opened 4 new positions and closed 2 in Q3 2023.
  • Rhenman & Partners Asset Management's portfolio value fell 2.2% quarter-over-quarter to $928M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.